Study of L19IL2 and L19TNF for advanced skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, L19IL2 and L19TNF, which are injected directly into skin tumors. It is for patients with advanced cutaneous squamous cell carcinoma that has not responded to or cannot tolerate immune checkpoint inhibitor therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of skin cancer called cutaneous squamous cell carcinoma that has spread locally and cannot be removed by surgery.
- You have at least one skin or under-the-skin tumor that can be injected and measured.
- Your cancer has gotten worse during or after treatment with an immunotherapy drug (checkpoint inhibitor), or you cannot tolerate that treatment.
- You are willing to have a small tissue sample (biopsy) taken from a tumor before and during the study.
- You are at least 18 years old and your overall health status allows you to be up and about (ECOG score 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (an immunotherapy and an EGFR inhibitor) given before surgery to shrink locally advanced skin cancer and potentially make surgery easier or more successful. It may help people whose skin cancer is hard to treat with surgery alone.
This Phase 1 trial studies adding atezolizumab (an immune therapy) to radiation for people with hard-to-remove or borderline-resectable cutaneous squamous cell carcinoma (cSCC). The goal is to see whether this combination can better control the cancer and whether the treatment is safe.
This trial tests a combination drug (L19IL2/TNF) given as injections into skin tumors. It is for people with advanced basal cell carcinoma that has worsened after or cannot tolerate standard treatments.
This trial tests a combination of two drugs, L19IL2 and L19TNF, injected directly into advanced basal cell carcinoma tumors that cannot be treated with surgery or radiation. The goal is to see if these drugs can shrink the tumors.
This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
Hear when a new Locally Advanced Cutaneous Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.